64 results about "Β cryptoxanthin" patented technology

The present invention explains a realistic and effective process for isolating and purifying carotenoids containing higher concentrations of carotenoids such as trans-lutein, trans-zeaxanthin, Cis-lutein, β-carotene and Cryptoxanthin from Marigold flower petals under controlled conditions leaving no traces of any organic hazardous solvents. The process involves ensilaging Marigold flowers, dehydration, solvent extraction, alkali hydrolysis of carotenoid esters with absolute alcohol, crystallization / purification using water, absolute alcohol mixture followed by filteration and drying until the crystals are considerably free from moisture and absolutely free from residual hazardous solvents. These crystals are suitable for nutraceutical and food products as supplements.

A composition which has high safety and is excellent in the effect of reducing body fat, such as visceral fat, subcutaneous fat and the like, and neutral fat, and a food, a pharmaceutical and a feed comprising the same, are provided. An oral administration composition having a body fat reducing action and / or a neutral fat reducing action, which is a composition comprising a carotenoid and a sphingolipid or a carotenoid and a flavonoid and / or a derivative thereof, preferably a composition comprising a cryptoxanthin and a sphingolipid or a cryptoxanthin and a flavonoid and / or a derivative thereof, wherein the cryptoxanthin and / or the sphingolipid and / or the flavonoid are derived from a citrus fruit and the citrus fruit is preferably Citrus unshiu.

The present invention relates to a process for converting lutein and / or lutein esters to (3R)-β-cryptoxanthin and (3R,6′R)-α-cryptoxanthin, suitable for human consumption as dietary supplements, by employing safe and environmentally friendly reagents. (3R)-β-Cryptoxanthin and (3R,6′R)-α-cryptoxanthin are two rare food carotenoids that are not commercially available and the former exhibits vitamin A activity. In the first synthetic step, commercially available lutein and / or lutein esters are transformed into a mixture of dehydration products of lutein (anhydroluteins) in the presence of a catalytic amount of an acid. The resulting anhydroluteins are then converted to (3R)-β-cryptoxanthin (major product) and (3R,6′R)-α-cryptoxanthin (minor product) by heterogeneous catalytic hydrogenation employing transition elements of group VIII (Pt, Pd, Rh supported on alumina or carbon) in a variety of organic solvents under atmospheric pressure of hydrogen and at temperatures ranging from −15° C. to 40° C. Among these catalysts, Pt supported on alumina at 40° C. in ethyl acetate provides the best yield of (3R)-β-cryptoxanthin and (3R,6′R)-α-cryptoxanthin. Several homogeneous catalysts can also promote the regioselective hydrogenation of anhydroluteins to a mixture of (3R)-β-cryptoxanthin and (3R,6′R)-α-cryptoxanthin in low to moderate yields. The catalysts may be transition metal complexes such as palladium acetylacetonate, Rh(Ph3P)3Cl (Wilkinson's catalyst), [(C6H11)3P[C8H12][C5H5N] Ir+PF6− (Crabtree catalyst), or [C8H12][(MePh2P)2]Ir+PF6−. Among these, Wilkinson catalyst converts anhydroluteins to (3R)-β-cryptoxanthin and (3R,6′R)-α-cryptoxanthin in nearly quantitative yield. A novel feature of this invention is the regioselective hydrogenation of anhydroluteins while the highly conjugated polyene chain of these carotenoids remains intact.

A carotenoid producing bacterium belonging to the genus Paracoccus that selectively produces canthaxanthin so that the amount thereof is not less than 90 percent by weight of the total amount of produced carotenoids including β-carotene, β-cryptoxanthin, echinenone, canthaxanthin, 3-hydroxyechinenone, 3′-hydroxyechinenone, zeaxanthin, phoenicoxanthin, adonixanthin, and astaxanthin. A method for producing canthaxanthin by culturing the above bacterium, and then collecting carotenoids from bacterial cells or a culture solution after the culturing.

Mushrooms genetically engineered to produce provitamin A carotenoids including α-carotene, β-carotene, γ-carotene, and β-cryptoxanthin are provided. In some embodiments, mushrooms are transformed with genes that encode enzymes that have phytoene synthase, pyhtoene dehydrogenase and lycopene cyclase activities and function to convert GGPP to one or more provitamin A carotenoids. Mushrooms are transformed using known methods, including Agrobacterium-mediated transformation. Transgenic mushrooms producing provitamin A carotenoids are useful to treat, alleviate, reduce, and / or inhibit one or more symptoms of a disease or disorder associated with vitamin A deficiency (VAD).

A marigold plant, a regenerable portion thereof and seed are disclosed whose flower petals, leaves or flower petals and leaves contain one or more of an enhanced neoxanthin plus violaxanthin ratio, an enhanced β-carotene ratio, an enhanced lycopene ratio, an enhanced α-cryptoxanthin ratio, an enhanced phytoene ratio or an enhanced phytofluene ratio relative to that ratio in a non-mutant marigold. A marigold plant, a regenerable portion thereof and seed are also disclosed whose flower petals contain zeaxanthin esters and are substantially free of esters of both neoxanthin and violaxanthin, and wherein zeaxanthin constitutes at least about one-half of the extractable carotenoids when xanthophylls are assayed as alcohols. Also disclosed are methods of preparing such plants, oleoresins and comestible materials that have such carotenoid ratios.